Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer.

According to documents submitted by Conduent Inc to the U.S. Securities and Exchange Commission (SEC), the buyer in the related transaction will retain a holdback amount of 10 million dollars for one year, as well as an additional special holdback amount of 12 million dollars.

According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the U.S. Centers for Medicare & Medicaid Services (CMS) has updated the Medicare reimbursement standards for non-invasive bone growth stimulators.

According to documents submitted to the U.S. Securities and Exchange Commission (SEC), SEACOR Marine Holdings Inc. is about to receive a total fund release of $13.7 million from its restricted escrow account.

According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027.